<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791959</url>
  </required_header>
  <id_info>
    <org_study_id>046466</org_study_id>
    <nct_id>NCT01791959</nct_id>
  </id_info>
  <brief_title>The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory
      factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50
      patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be
      randomly allocated to receive 2 protexin capsules or placebos for 7 months; both groups will
      be advised to adherence our diet and exercise program too. At the first and the end of the
      intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis
      will be assessed and compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alaninaminotransferase (ALT)</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 synbiotic capsules for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodexterin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two capsules per day for 28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>synbiotic</intervention_name>
    <description>2 symbiotics capsules per day for 28 weeks</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 Maltodexterin capsules as a placebo per day for 28 weeks</description>
    <arm_group_label>maltodexterin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years

          -  Body Mass Index (BMI) between 25-40

          -  Serum alaninaminotransferase more than 1.5 fold of upper limit of normal range

          -  Sonographic findings compatible with hepatic steatosis (degree 2 or more)

        Exclusion Criteria:

          -  Diabetes

          -  Taking any kind of antibiotics two weeks before recruitment

          -  History of alcohol consumption

          -  pregnancy or lactation

          -  Professional athletes

          -  Other liver disease (viral/etc)

          -  Use of drugs such as calcium channel blockers, high dose synthetic estrogens,
             methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs,
             lipid-lowering agents, metformin and vitamin E

          -  A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease &amp;
             Celiac disease; Cirrhosis

          -  History of Upper GI surgery / Prior surgical procedures such as jejunoileal or
             jejunocolic bypass, gastroplasty

          -  Following program to lose weight in recent 3 mo

          -  A history of hypothyroidism or Cushing's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azita Hekmatdoost, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Nutrition and Food Technology Research Institute</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

